Update shared on 02 Dec 2025
Analysts have maintained their price target for AlzChem Group at €167.10. They cite steady outlooks for revenue growth and profit margins, with only minor adjustments to the discount rate and future earnings projections.
What's in the News
- AlzChem Group AG has provided earnings guidance for the full year 2025 and expects another record year, forecasting sales growth to around EUR 580 million (Key Developments).
- New cooperation announced: Starting in October 2025, Ehrmann and AlzChem Group AG will launch a range of high-protein creatine products featuring Creavitalis®. These will be available as puddings, drinks, and bars (Key Developments).
- The new product line with Creavitalis® offers convenient, scientifically proven creatine in everyday foods, free of sugar, lactose, and gluten, and low in fat (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at €167.10.
- Discount Rate has risen slightly from 5.25% to 5.26%.
- Revenue Growth outlook is stable at 9.59%.
- Net Profit Margin shows no significant change, holding at approximately 13.56%.
- Future P/E ratio has increased marginally from 17.05x to 17.06x.
Have other thoughts on AlzChem Group?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.